Anesiva

company

About

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
$50.37M
Industries
Biotechnology,Genetics,Health Care,Medical,Therapeutics
Founded date
Jan 1, 1999
Number Of Employee
51 - 100
Operating Status
Close

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

On June 10, 2014 filed for Chapter 7 bankruptcy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$50.37M
Anesiva has raised a total of $50.37M in funding over 2 rounds. Their latest funding was raised on Jul 23, 2002 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 23, 2002 Series C $50.37M 1 Bear Stearns Health Innoventures L.P Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Anesiva is funded by 1 investors. Bear Stearns Health Innoventures L.P are the most recent investors.
Investor Name Lead Investor Funding Round
Bear Stearns Health Innoventures L.P Yes Series C